Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood count may forecast deadly transplant complication

NCT ID NCT07508345

Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether counting a specific type of cell in the blood (circulating endothelial cells) can predict the risk of acute graft-versus-host disease (GVHD) in adults receiving a stem cell transplant for blood cancer. Researchers measured these cells before transplant in 50 patients. The goal was to see if higher counts could identify those more likely to develop GVHD, a serious immune reaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to identify patients at high risk for acute GVHD before symptoms appear.
What could go wrong
This is a small, completed observational study, not a treatment trial. The findings may not be confirmed in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Jun 2021

Finished

Jul 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with hematological diseases undergoing allogeneic hematopoietic stem cell transplantation at the Hematology Unit of the I.R.C.C.S. Policlinico San Matteo Foundation in Pavia.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 70 years old * First allogeneic hematopoietic stem cell (HSC) transplant for hematological disease * Use of HSCs from bone marrow, peripheral blood, or cord blood * Use of HLA-identical related donors, haploidentical related donors, HLA-identical registry donors, registry donors with mismatches at major HLA loci * Signing of informed consent Exclusion Criteria: * Age \< 18 years or \>70 years * Patients receiving allogeneic HSC transplantation for non-hematologic disease * Second or subsequent allogeneic HSC transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    Pavia, Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.